Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program

Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards…

Source: FiercePharma